Influence of meldonium on the Quality of Life of patients with Coronary Artery Disease and Concomitant Arterial hypertension During the Recovery Treatment period After percutaneous Coronary Intervention

Abstract

Aim: To evaluate the impact of meldonium on the quality of life of patients with CAD and concomitant AH during the recovery treatment period after percutaneous coronary intervention (PCI). Materials and methods: The study included 66 patients with CAD, stable angina pectoris II-III functional class and concomitant stage II-III AH, who underwent percutaneous coronary intervention (PCI). Patients were divided into 2 groups. The first group – patients who received meldonium at a dose of 750 mg/d for 6 months in addition to basic therapy, the second group – patients who continued basic therapy. Patients’ health related quality of life (HRQoL) was assessed using the Ukrainian versions of the Seattle Angina Questionnaire, SF-36 Health Status Survey and MacNew Heart Disease HRQL questionnaires. Additionally the need for sublingual nitroglycerin, the frequency of angina attacks per day were evaluated and 6-minute walk test was performed according to standard methods. Results: Additional use of meldonium improved patients` HRQoL. It also led to reducing the number of angina attacks from 3,02 to 1,23 in 1 month and up to 0,62 in 6 months. The frequency of nitroglycerin administration during the day in this group also decreased from 2,22 doses to 1,24 doses after 1 month and to 0,62 doses after 6 months. Conclusions: Meldonium improves the HRQoL of patients with CAD and concomitant AH during the recovery treatment period after PCI. Additional use of meldonium helps to reduce the number of angina attacks in patients with CAD and concomitant AH and reduces the number of daily doses of nitroglycerin.